A5000166407- Ethics in Clinical Research
- Dementia and Cognitive Impairment Research
- Patient-Provider Communication in Healthcare
- Pharmaceutical Practices and Patient Outcomes
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
- Balance, Gait, and Falls Prevention
- Parathyroid Disorders and Treatments
- Biomedical Ethics and Regulation
- Paraoxonase enzyme and polymorphisms
- Medical Research and Practices
- Health and Medical Research Impacts
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Medical and Biological Sciences
- Vitamin C and Antioxidants Research
- Autism Spectrum Disorder Research
- Functional Brain Connectivity Studies
- Botulinum Toxin and Related Neurological Disorders
- Neurological disorders and treatments
- Genomics and Rare Diseases
- BRCA gene mutations in cancer
- Parkinson's Disease Mechanisms and Treatments
- Health Policy Implementation Science
- Health, Environment, Cognitive Aging
University of Pennsylvania
2024
Alzheimer’s Disease Neuroimaging Initiative
2019-2022
University of Wisconsin–Madison
2019-2022
William S. Middleton Memorial Veterans Hospital
2019
Geriatric Research Education and Clinical Center
2019
UK Dementia Research Institute
2019
Alzheimer's Association
2019
Washington University in St. Louis
2019
University of California, San Francisco
2019
University College London
2019
This study investigated differences in retrospective cognitive trajectories between amyloid and tau PET biomarker stratified groups initially cognitively unimpaired participants sampled from the Wisconsin Registry for Alzheimer's Prevention. One hundred sixty-seven individuals (baseline age 59 ± 6 years; 115 females) were by elevated amyloid-β status based on 11C-Pittsburgh compound B (PiB) 18F-MK-6240 imaging. Mixed effects models used to determine if longitudinal a composite of tests...
To examine whether the
Occupational exposure to organophosphate pesticides, such as chlorpyrifos (CPF), increases the risk of Alzheimer's disease (AD), though mechanism is unclear. To investigate this, we subjected 4-month-old male and female wild-type (WT) TgF344-AD rats, a transgenic AD model, an occupational CPF paradigm that recapitulates biomarkers behavioral impairments experienced by agricultural workers. Subsequent cognition neuropathology were analyzed over next 20 months. caused chronic microglial...
Alzheimer's disease (AD) begins with an asymptomatic "preclinical" phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Research is increasingly focused on validating to improve reliable diagnosis and timely clinical treatment of AD. Most preclinical biomarker research lacks adequate representation Black/African American other racially ethnically minoritized individuals, limiting the applicability data these groups. This may exacerbate existing disparities...
We examined factors related to willingness enroll in hypothetical Alzheimer disease (AD) biomarker studies.Using linear regression, we assessed the relationship among enrollment and demographics, family dementia history, research attitudes, concern about AD, experiences of discrimination, belief AD risk modifiability. Inductive coding was used assess qualitative data.In middle-aged older adult participants (n=334), studies driven by collection method, disclosure personal results. Predictors...
Alzheimer's disease (AD) begins with an asymptomatic "preclinical" phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed research settings, and moving toward clinical settings the development of cheaper non-invasive testing. Limited has focused on safety psychological effects disclosing biomarker results to cognitively unimpaired adults. However, less known about how ensure equitable access robust...
The present study investigated: 1) sex differences in polypharmacy, comorbidities, self-rated current health (SRH), and cognitive performance, 2) associations between SRH, objective measures of health, 3) these factors with longitudinal performance. Analyses included 1039 eligible Wisconsin Registry for Alzheimer's Prevention (WRAP) participants who were cognitively unimpaired at baseline had ≥2 visits composites, self-reported history, concurrent medication records. Repeated correlation...
As more is understood about the hereditary nature of disease risk, utility genetic testing within cardiovascular medicine increasingly being explored. Although may afford personalized risk stratification, there a paucity information regarding patient knowledge, attitudes, and beliefs toward among cardiology patients. Participants (n = 530) recruited primarily from clinic filled out 41-item written questionnaire assessing beliefs, attitudes testing, motivators detractors for considering...
Abstract Background Best practice recommendations suggest a person close to patient with mild cognitive impairment (MCI) or dementia be involved in their care. This is often referred as “caregiver,” though the term “care partner” has increasingly been used research and care instead of “caregiver.” Unlike suggests collaborative relationship between support person, which actively participates rather than passively receives help. It not known, however, what nomenclature people this role...
Abstract Background When and how to communicate effectively the results of genetic biomarker based prediction, detection, quantification brain substrates dementia involve important ethical legal issues critical for precision medicine. The urgency issue has increased as People Living with Dementia (PLwD) Risk (PwRD) can access direct consumer testing, amyloid targeting drugs, clinical PET scans. To address need effective dissemination consultation, an advisory group was convened that welcomes...
Abstract Background Aging is often accompanied by the accumulation of chronic illnesses such as diabetes, cardiovascular disease or hypertension and a corresponding increase in use medications to manage these conditions. Polypharmacy (use multiple prescription medications) growing health concern has been associated with poorer clinical outcomes older adults. This study investigates associations between comorbidities, polypharmacy longitudinal cognitive performance an Alzheimer’s (AD)...
Abstract Background Literature on factors influencing the decision to enroll in Alzheimer’s biomarker research increasingly indicates that study partners are important this decision. Limited suggests participants comfortable sharing their results within close relationships context of clinical trials. It is unknown how feel about non‐clinical trial studies, which may be similar future settings risk information shared without an available trial. Our objective was understand whether and why...
Abstract With improved detection of Alzheimer’s disease and biomarker accessibility, more adults with no or mild symptoms may learn their AD results. Yet, potential psychosocial impact learning biomarkers is not well understood. In a phone survey, we assessed reactions after about hypothetical positive result. Data were collected from cognitively healthy participants (n=334, mean age=64.8±7.7) enrolled in longitudinal studies. Exploratory factor analysis identified five latent factors...
Abstract Background With improved temporal identification and characterization of AD biomarkers, disclosure personal biomarker information will become increasingly relevant. Understanding participant factors related to willingness learn such may inform relationship‐building with communities, especially those historically excluded from biomedical research, aid the development guidelines for safe, effective disclosure. Method We developed a 30‐minute phone survey gather Black W participants on...
Abstract Background Alzheimer’s disease (AD) diagnostics is evolving rapidly, moving toward biomarker‐based diagnoses characterized by amyloid, tau, and neurodegeneration. To clarify benefits risks of using this framework with cognitively unimpaired adults, particularly those from groups under‐represented in AD biomarker research, we developed a 30‐minute telephone survey to identify factors predicting willingness enroll studies hypothetical disclosure‐related outcomes. Method Existing...
Abstract Background Studies of anticholinergic (AC) medications (drugs that block acetylcholine neurotransmitter action) have shown associations between the AC use, cognitive impairment, and increased dementia risk. Associations medication AD biomarkers among cognitively normal late middle‐aged adults are unclear. This study examined cognition, physical health, amyloid PET measures. Methods Wisconsin Registry for Alzheimer’s Prevention (WRAP) participants with >=3 composite scores, free...